Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,473.60
(
0.27%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.40
(
-2.18%
)
Bitcoin
73,398.93
(
2.24%
)
News Focus
News Focus
Post# of 257376
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biopharm investor post# 20927

Wednesday, 12/21/2005 5:15:31 PM

Wednesday, December 21, 2005 5:15:31 PM

Post# of 257376
Re: Terminology

>Even what is meant by "late-stage" is somewhat debatable. "Late-stage" to me means drugs that are in registration-based clinical trials. Many view "late-stage" to mean only drugs that have been filed or will soon be filed.<

How about we discard the “late stage” qualifier and use phase-3 and launch-ready instead?

As far as PFE is concerned, the launch-ready pipeline (Exubera, Sutent, Indiplon) is more impressive than the phase-3 pipeline, IMO.

p.s. Looking forward to your reply on PFE, TEVA, AGN, BIIB, FRX, etc.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today